# Kadcyla In pAtients With bRAin Metastasis

> **NCT03203616** · PHASE2 · WITHDRAWN · sponsor: **Jules Bordet Institute**

## Conditions studied

- Metastatic HER2-positive Breast Cancer With Brain Metastasis

## Interventions

- **DRUG:** KADCYLA 160 MG Injection

## Key facts

- **NCT ID:** NCT03203616
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-02-23
- **Primary completion:** 2018-08-27
- **Final completion:** 2018-08-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** As most HER2+ patient develop brain mets while on/after having received TDM1, it has proven to be an insurmountable challenge to recruit patients
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03203616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03203616, "Kadcyla In pAtients With bRAin Metastasis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03203616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*